## No Change in the National Utilization of Cemented Stem Fixation for Elective Total Hip Arthroplasty from 2015 to 2021

Thomas Insuk Hong, Amil Raj Agarwal, JUSTIN THOMAS SAMUEL, Majd Marrache, Jordan Cohen<sup>1</sup>, Sandesh Rao, Gregory Golladay<sup>2</sup>, Savyasachi C Thakkar

<sup>1</sup>University of Pennsylvania Hospital, <sup>2</sup>VCU Health

Av

Prior

Chron

CCI: Charl

INTRODUCTION: Cementless fixation is most commonly used for elective total hip arthroplasty (THA) in the United States (US). However, cemented stems have less risk of fracture and loosening, particularly in older patients with poor bone quality. Given the aging population, the purpose of this study was to examine 1) factors associated with cemented stem fixation and 2) changes in US cemented stem fixation utilization for THA from 2015 to 2021.

METHODS: A retrospective analysis of patients undergoing cemented or cementless THA stem fixation between 2015 and 2021 was conducted using a national administrative database. Patient characteristics were compared for each fixation type. Subsequently, the change in utilization of cemented fixation as the THA fixation type was observed from 2015 to 2021 for all patients as well as for different subgroups. Among the 275,108 THA patients identified, 27,783 (10.1%) underwent cemented stem fixation.

RESULTS: Patients who underwent cemented fixation were significantly older, more likely to be female, have osteoporosis, a prior fragility fracture, rheumatoid arthritis, chronic kidney disease, Medicaid, Medicare, and to be from the South (p<0.001). Between 2015 to 2021, there was no significant change in the utilization of cemented fixation in the general population (p=0.230), patients aged 75+ (p=0.526), those with prior fragility fractures (p=0.098), or those with a diagnosis of osteoporosis (p=0.134).

DISCUSSION AND CONCLUSION: Despite studies favoring cemented femoral stem fixation in patients with poor bone health, our study showed no difference in the national utilization of cemented stem fixation for total hip arthroplasty. Clinical practice guidelines guidelines and cemented method in at-risk patients. Table 1. Demographic and Comorbidities of Patients Undergoing Cemented and Cemented stem fixation in at-risk patients.

CAGR: Compounded Annual Growth Rate: CCI: Charlson Comorbidity Index: BMI: Body Mass Inde

Arthroplasty						d Cemented	Multivariable Analysis	Multivariable Analysis						Table 51 Hends in Gunzalon of Centencess Total Hip Futurophasty, Subgroup Futurysis									
Category	Total	Ce	mented	Cer	nentless		Category	Odds Ratio	95% CI	P-value	-	TOTAL	11.5%	9.8%	8.7%	9.0%	10.1%	11.1%	14.9%	4.43%	-		
-	Number	Number	Percent	Number	Percent	P-value	AGE					101112	-	-	-								
TOTAL	276,434	27,783	10.05%	248,651	89.95%		<55	REF	REF	REF		<50	9.0%	7.2%	6.2%	6.0%	7.3%	7.2%	13.5%	6.92%			
erage Age (Years)		70.04	SD (10.499)	65.99	SD (10.55)	< 0.001	55-64	0.99	0.93-1.04	0.694		50-59	7.5%	6.5%	6.0%	6.1%	6.6%	6.6%	9.5%	3.90%			
Sex					-	< 0.001	65-74	1.15	1.09-1.20	<0.001		60-69	9.2%	7.3%	6.2%	5.9%	7.1%	8.0%	10.1%	1.63%			
Female	159061	18289	65.83%	140772	56.61%		75+	2.16	2.06-2.27	<0.001		70-74	11.6%	9.5%	8.6%	8.9%	9.9%	10.5%	13.1%	2.09%			
Male	117373	9494	34.17%	107879	43.39%		Ser		-	-		75+	20.3%	16.9%	14.7%	15.5%	16.4%	18.5%	22.0%	1.36%			
Average CCI	N/A	2.58	SD (2.20)	2.01	SD (2.72)	< 0.001	Famala	DEE	DEE	DEE		Sex											
Osteoporosis	18051	2704	9.73%	15347	6.17%	< 0.001	Mala	0.78	0.76.0.80	<0.001		Female	13.2%	11.1%	10.1%	10.4%	11.4%	12.8%	16.8%	4.10%			
OP treatment	24,724	3,902	14.04%	20822	8,37%	< 0.001	, mare	0.78	0.70-0.00	-0.001		Male	9.4%	8.1%	6.9%	7.2%	8.3%	8.7%	12.1%	4.27%			
Fragility Fracture	29010	4472	16.10%	24538	9.87%	< 0.001	ter .	DEE	DEE	DEE		cci	-	-	-					-			
Diabetes Mellitus	13557	1411	5.08%	12146	4.88%	0.142	0	REF	KEF	REF		0	10.1%	7.7%	7.3%	8.2%	8.5%	8.3%	9.1%	-1.75%			
Tobacco Use	9246	843	3.03%	8403	3.38%	0.004	1+	1.06	1.06-1.07	<0.001		1	11.1%	9.0%	7.6%	8.1%	9.5%	9.8%	13.7%	3.58%			
cight (BMI < 18.5)	4723	693	2.49%	4030	1.62%	<0.001	Osteoporosis	611	1.06-1.16	<0.001		2	11.0%	10.2%	8.8%	9.1%	10.1%	10.8%	10.4%	5.92%			
eumatoid Arthritis	20167	2491	8.97%	17676	7.11%	<0.001	OP treatment	1.26	1.21-1.31	<0.001		0.4	15.176	12.376	12.0%	12.49/	12.4%	14.9%	22.8%	8.8576			
Dementia	13753	2449	8.81%	11304	4.55%	< 0.001	Prior Fragility Fracture	1.35	1.26-1.45	<0.001		OB transforment	17.9%	15.2%	14.4%	13.4%	15.0%	16.6%	21.7%	3.4194			
ic Kidney Disease	3406	626	2.25%	2780	1.12%	< 0.001	Diabetes Mellitus	0.88	0.84-0.94	<0.001		Prior Fragility Fracture	3 396	3.4%	3.6%	2.6%	2.9%	2.3%	2.6%	-4.01%			
Insurance Type						<0.001	Tobacco Use	1.04	0.97-1.12	0.240		Diabetes Mellitus	10.9%	10.8%	10.5%	8.5%	10.2%	10.8%	15.5%	5.94%			
Commercial	165307	14284	51.41%	151023	60.74%		Underweight (BMI <18.5)	1.18	1.09-1.28	<0.001		Tobacco Use	8.2%	9.6%	9.4%	7.4%	8.7%	10.2%	13.9%	9.16%			
Government	2937	215	0.77%	2722	1.09%		Rheumatoid Arthritis	1.15	1.10-1.21	<0.001		Underweight (BMI	10.00/			10.00		10.000	AL 194				
Medicaid	11047	954	3 43%	10093	4.06%		Dementia	1.21	1.16-1.27	<0.001		<18.5)	13.2%	14.5%	13.1%	12.7%	14.4%	16.2%	21.5%	8.41%			
Medicare	95897	12248	44.08%	83649	33.64%		Chronic Kidney Disease	1.59	1.45-1.74	<0.001		Domantia	19.076	17.2%	16.2%	18.0%	17.9%	10.3%	22.6%	3.95%			
Unknown	757	58	0.21%	699	0.28%		Insurance					Chronic Kidney Directo	19.0%	17.4%	14 8%	18 1%	16.7%	25.1%	26.9%	6.01%			
Region		50	0.2174		0.2074	<0.001	Commercial	REF	REF	REF		Insurance			14.074	10.174							
Midward	76950	6693	24.05%	20126	28 2284		Government	0.94	0.83-1.08	0.392		Commercial	10.0%	8.2%	7.6%	7.8%	8.7%	9.5%	12.8%	4.14%			
Northeart	70179	6431	23.15%	63748	25.64%		Medicaid	1.28	1.20-1.36	<0.001		Government	10.9%	7.7%	7.0%	4.9%	9.6%	3.5%	9.9%	-1.50%			
South	90544	9709	23.1376	20925	29.40%		Medicare	1.24	1.21-1.28	<0.001		Medicaid	10.2%	9.1%	7.5%	7.9%	7.3%	9.5%	12.9%	3.91%			
Wart	47619	4837	17 41%	42782	17 2186		Region					Medicare	14.5%	12.8%	10.9%	11.7%	12.5%	14.4%	18.0%	3.65%			
I talan marin	1019	102	0.449/	1110	0.459/		Midwest	REF	REF	REF		Region	-	-			-			-			
Onthown	1233	123	0.4476	1110	0.43%		Northeast	1.08	1.05-1.12	<0.001		Midwest	9.6%	8.8%	7.7%	8.0%	8.0%	10.0%	14.3%	6.81%			
son Comorbidity Index; BMI: Body Mass Index				South	1.41	1 37-1 46	<0.001		Northeast	11.8%	8.3%	8.1%	8.8%	9.0%	9.5%	12.4%	0.84%						
							Wast	1.16	1 11-1 20	<0.001		South	13.9%	11.9%	10.5%	10.4%	12.8%	12.6%	17.0%	3.45%			
							WEST	1.10	1.11/1.20	-0.001		West	11.2%	10.5%	8.9%	8.8%	10.0%	13.4%	18.5%	8.65%			

CI: Confidence Interval; CCI: Charlson Comorbidity Index; BMI: Body Mass Index